CL2016001604A1 - “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct - Google Patents

“compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct

Info

Publication number
CL2016001604A1
CL2016001604A1 CL2016001604A CL2016001604A CL2016001604A1 CL 2016001604 A1 CL2016001604 A1 CL 2016001604A1 CL 2016001604 A CL2016001604 A CL 2016001604A CL 2016001604 A CL2016001604 A CL 2016001604A CL 2016001604 A1 CL2016001604 A1 CL 2016001604A1
Authority
CL
Chile
Prior art keywords
axl
pharmaceutical composition
pyrazolo
pyridine
pct
Prior art date
Application number
CL2016001604A
Other languages
English (en)
Inventor
Robert L Hudkins
Allison L Zulli
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of CL2016001604A1 publication Critical patent/CL2016001604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

LA SOLICITUD SE REFIERE A COMPUESTOS DERIVADOS DE PIRAZOLO[1,5-A]PIRIDINA, INHIBIDORES DE QUINASAS AXL Y C-MET, A UNA COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y A SU USO EN EL TRATAMIENTO DEL CÁNCER.
CL2016001604A 2013-12-26 2016-06-21 “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct CL2016001604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26

Publications (1)

Publication Number Publication Date
CL2016001604A1 true CL2016001604A1 (es) 2017-05-26

Family

ID=52293273

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001604A CL2016001604A1 (es) 2013-12-26 2016-06-21 “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct

Country Status (22)

Country Link
US (2) US9914731B2 (es)
EP (2) EP3087070B1 (es)
JP (1) JP2017500362A (es)
KR (1) KR20160110390A (es)
CN (1) CN106029661B (es)
AU (1) AU2014370186A1 (es)
BR (1) BR112016015057A2 (es)
CA (1) CA2934667A1 (es)
CL (1) CL2016001604A1 (es)
DK (1) DK3087070T3 (es)
EA (2) EA201890061A3 (es)
ES (1) ES2654931T3 (es)
HU (1) HUE037579T2 (es)
IL (1) IL246311A0 (es)
MX (1) MX2016008445A (es)
NO (1) NO3014707T3 (es)
PH (1) PH12016501232A1 (es)
PL (1) PL3087070T3 (es)
PT (1) PT3087070T (es)
SG (1) SG11201605207PA (es)
SI (1) SI3087070T1 (es)
WO (1) WO2015100117A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3322706T3 (pl) * 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
AU2017395023B2 (en) * 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US11623923B2 (en) * 2017-11-24 2023-04-11 Medshine Discovery, Inc. Uracil compound as c-MET/AXL inhibitor
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
KR20210049862A (ko) * 2018-08-24 2021-05-06 난징 트렌스테라 바이오사이언스즈 컴퍼니 리미티드 일종의 신형 퀴놀린 유도체 억제제
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的***并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
EP4029862A4 (en) * 2019-09-06 2023-10-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences CONNECTION WITH AXL AND C-MET KINASE INHIBITORY ACTIVITY, THEIR PREPARATION AND USE
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023286719A1 (ja) * 2021-07-13 2023-01-19 日本曹達株式会社 ウラシル化合物の製造方法
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
AU2007224020A1 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
RU2009126576A (ru) * 2006-12-12 2011-01-20 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2011079804A1 (en) * 2009-12-31 2011-07-07 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
BR112013021638A2 (pt) * 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
CN103717600B (zh) * 2011-08-10 2016-06-22 默克专利股份公司 吡啶并嘧啶衍生物
MX2014002990A (es) * 2011-09-19 2014-05-21 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
SG10201510307WA (en) * 2011-11-14 2016-01-28 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
WO2015100117A1 (en) 2015-07-02
EP3087070B1 (en) 2017-11-08
US20180148447A1 (en) 2018-05-31
BR112016015057A2 (pt) 2017-08-08
HUE037579T2 (hu) 2018-09-28
PH12016501232A1 (en) 2016-08-15
PL3087070T3 (pl) 2018-03-30
SG11201605207PA (en) 2016-07-28
CN106029661A (zh) 2016-10-12
EP3309160A1 (en) 2018-04-18
CA2934667A1 (en) 2015-07-02
NO3014707T3 (es) 2018-01-06
ES2654931T3 (es) 2018-02-15
MX2016008445A (es) 2016-10-28
PT3087070T (pt) 2018-01-30
KR20160110390A (ko) 2016-09-21
US9914731B2 (en) 2018-03-13
AU2014370186A1 (en) 2016-07-14
AU2014370186A2 (en) 2016-07-21
EA201890061A3 (ru) 2018-09-28
CN106029661B (zh) 2017-11-03
SI3087070T1 (en) 2018-01-31
DK3087070T3 (en) 2017-12-04
EA201691164A1 (ru) 2016-12-30
US20160318929A1 (en) 2016-11-03
IL246311A0 (en) 2016-08-02
EP3087070A1 (en) 2016-11-02
JP2017500362A (ja) 2017-01-05
EA029757B1 (ru) 2018-05-31
EA201890061A2 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2015002303A1 (es) Derivados de pirrolo[2,3-d]pirimidina
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CR20150524A (es) Compuestos de heteroarilo y sus usos
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
CL2015002060A1 (es) Compuestos.
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ